Filing summary
Entity mismatch: The supplied filing is Leap Therapeutics, Inc. (Nasdaq: LPTX), not Cypherpunk Technologies Inc. It is a Form 10-Q for the quarter ended June 30, 2022, filed August 12, 2022. The summary below reflects the filing provided.
Business context and period
Leap is a clinical-stage biopharmaceutical company developing cancer therapies. Its lead candidate, DKN-01, is being studied in multiple clinical trials; it has not been approved by the FDA, and the company has no product sales. BeiGene holds an option and license covering DKN-01 in Asia (excluding Japan), Australia, and New Zealand; Leap retains rights elsewhere.
Financial performance and position
| Metric | Q2 2022 / June 30, 2022 | Comparable period / prior balance |
|---|---|---|
| Revenue | $0 | Q2 2021: $0.375 million |
| Research and development expense | $14.045 million | Q2 2021: $7.206 million |
| General and administrative expense | $2.855 million | Q2 2021: $2.795 million |
| Net loss | $17.024 million; $0.15 per share | Q2 2021: $9.526 million; $0.12 per share |
| Cash and cash equivalents | $90.883 million | December 31, 2021: $114.916 million |
| Total assets | $94.203 million | December 31, 2021: $117.911 million |
| Total liabilities | $10.885 million | December 31, 2021: $10.024 million |
| Stockholders’ equity | $83.318 million | December 31, 2021: $107.887 million |
For the six months ended June 30, 2022, revenue was zero, operating expenses were $27.532 million, and net loss was $27.400 million. Operating cash use was $23.777 million, versus $16.339 million in the first half of 2021. Cash declined by $24.033 million during the half. The filing reports no conventional borrowings; lease liabilities totaled $0.869 million, including $0.395 million current. Profit margins are not meaningful given the lack of product sales and continuing losses.
Material changes and notable developments
- Q2 R&D expense rose $6.839 million year over year, mainly from higher DKN-01 manufacturing costs ($5.2 million) and clinical-trial costs ($1.2 million). First-half R&D expense increased $7.816 million, primarily from manufacturing and clinical-trial spending.
- BeiGene upfront-fee revenue recognized in 2021 was fully recognized by December 31, 2021; no BeiGene license revenue was recorded in 2022 through June 30.
- Foreign-currency losses were $0.733 million in Q2 2022 and $0.498 million in the first half, compared with $0.129 million and $0.150 million, respectively, in 2021.
- Cash and cash equivalents were $90.883 million at quarter-end. Management said this was sufficient to fund operating expenses for at least 12 months from issuance of the financial statements, while also expecting operating losses to continue.
- In July and August 2022, cashless exercises of pre-funded warrants resulted in issuance of 10,702,922 shares. The filing reported 99,021,376 common shares outstanding as of August 10, compared with 88,318,454 issued and outstanding at June 30.
Outlook, risks, and contingencies
Management plans to increase R&D spending as DKN-01 development continues, subject to funding availability. It said the timing and cost of development, trial outcomes, regulatory approvals, and potential future cash inflows cannot be reliably estimated. The company may seek equity financing, government-program funding, or collaboration and licensing support; without additional funding or cost-sharing, it may need to delay, reduce, or eliminate trials and other programs. No specific financial guidance was provided.
Clinical updates included initiation of Part C of the Phase 2 DisTinGuish study in gastroesophageal cancer and the Phase 2 DeFiance study in colorectal cancer. The filing also described preliminary investigator-sponsored prostate-cancer data: five evaluable patients in the DKN-01/docetaxel combination cohort had partial responses, while no partial responses were reported in the small monotherapy cohort. These are early clinical findings, not evidence of regulatory approval or established efficacy.
At June 30, the company had $12.0 million of noncancelable manufacturing commitments for DKN-01. It reported no material legal proceedings and no material changes to previously disclosed risk factors. Key risks include clinical and regulatory uncertainty, continued cash burn, dependence on additional funding and collaboration economics, manufacturing execution, and foreign-exchange exposure. The company disclosed no material change in internal control over financial reporting and said disclosure controls were effective.
Important facts for investors to verify
- Confirm the intended issuer: the supplied 10-Q is for Leap Therapeutics, not Cypherpunk Technologies.
- Review cash runway assumptions against actual quarterly cash burn, planned trial and manufacturing costs, and access to new financing.
- Track DKN-01 trial enrollment, endpoints, clinical results, safety, and regulatory requirements; the candidate remains investigational.
- Assess dilution from outstanding warrants, options, and restricted stock units. The filing lists 60.386 million warrants and 9.046 million options outstanding at June 30, as well as 3.511 million RSUs.
- Verify the timing and collectability of the $1.740 million Australian R&D incentive receivable and the status of the $12.0 million manufacturing commitments.